Patient advocates press safety concerns over Neurocrine's Prader-Willi drug Vykat XR
- STAT reports growing alarm among patient advocates and some experts over the perceived risks of Neurocrine's rare disease drug Vykat XR (diazoxide choline) for Prader-Willi syndrome.
- Earlier coverage links the concern to fluid retention, respiratory and cardiac events in post-marketing reports, though causality has not been established.
- Neurocrine has said it keeps a favourable benefit-risk view and is working with the FDA and patient groups.
💡 Points
This is a launch-curve story. Neurocrine paid heavily for Vykat XR as a blockbuster hopeful, and prescriber caution in a small, fragile patient population can slow uptake long before any regulatory action. The key variables are whether the label changes and whether the planned 2027 study in higher-risk patients reassures.
STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug ↗